Phacetoperane - NeuroLifeSciences

Drug Profile

Phacetoperane - NeuroLifeSciences

Alternative Names: NLS-3

Latest Information Update: 04 Dec 2015

Price : $50

At a glance

  • Originator NeuroLifeSciences
  • Class Acetates; Anorectics; Antidepressants; Esters; Piperidines; Small molecules
  • Mechanism of Action Central nervous system stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Attention-deficit hyperactivity disorder; Narcolepsy

Most Recent Events

  • 03 Dec 2015 Phase-I clinical trials in Attention-deficit hyperactivity disorder in France (unspecified route) prior to December 2015
  • 03 Dec 2015 Phase-I clinical trials in Narcolepsy in France (unspecified route)
  • 05 Feb 2015 NeuroLifeSciences has patent protection for phacetoperane in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top